|
1. |
Follicular Carcinoma of the Thyroid Gland: Prognostic Factors, Treatment, and Survival |
|
American Journal of Clinical Oncology: Cancer Clinical Trials,
Volume 23,
Issue 1,
2000,
Page 1-5
Jamal Zidan,
Samer Kassem,
Abraham Kuten,
Preview
|
|
摘要:
Prognostic variables and treatment outcomes of 82 patients treated at the Northern Israel Oncology Center were reviewed. There were 59 women and 23 men in this series. The female/male ratio was 2.6/1. Median age was 46 years. Median follow-up was 11.4 (range: 3.8–24 years). Median tumor size was 3.6 cm. When first seen, 4 patients had lymph node involvement and 11 (13%) had distant metastases. Surgical treatment was total thyroidectomy in 37 patients (45%), subtotal thyroidectomy in 38 (46%), and lesser procedures in 7 (9%). Sixty-six patients (80%) were treated after surgery with131I to ablate thyroid remnants. Doses ranged between 30 and 80 mCi. The 20-year overall actuarial survival rate was 65%. The actuarial survival rate of patients <40 years of age was 96% versus 33% in patients >50 years of age (p= 0.0008). Patients with distant metastases at presentation had inferior survival compared with patients without metastases. In conclusion, we found subtotal thyroidectomy followed by131I and hormone therapy to provide survival similar to that with total thyroidectomy, with less morbidity. Risk factors include: age ≥40 at the time of diagnosis, presence of distant metastases, capsular invasion, tumor size ≥2 cm, and male gender.
ISSN:0277-3732
出版商:OVID
年代:2000
数据来源: OVID
|
2. |
Comparison of Preoperative Embolization Followed by Radical Nephrectomy with Radical Nephrectomy Alone for Renal Cell Carcinoma |
|
American Journal of Clinical Oncology: Cancer Clinical Trials,
Volume 23,
Issue 1,
2000,
Page 6-12
Henryk Zielinski,
Stanislaw Szmigielski,
Zbigniew Petrovich,
Preview
|
|
摘要:
A series of 474 patients with renal cell carcinoma (RCC), who had radical nephrectomy during a period of 15 years, was studied to assess the prognostic significance of various pathologic parameters (tumor stage [pT], lymph node status, metastasis, tumor grade, venous involvement) and value of preoperative embolization of renal artery. There were: 20 (4%) pT1, 204 (43%) pT2, 245 (52%) pT3, and 5 (1%) pT4 patients. All 474 patients underwent nephrectomy including a group of 118 (25%) patients (24 pT2, 90 pT3, and 4 pT4) who underwent preoperative embolization of the renal artery. To compare treatment outcomes in embolized patients with RCC, a group of 116 (24%) nonembolized patients with RCC was selected. This group was matched for sex, age, stage, tumor size, and tumor grade, with the embolized patients (p < 0.01). All important prognostic factors were studied as to their influence on survival by the treatment group. The overall 5- and 10-year survival was 62% and 47%, respectively. The 5- and 10-year survival rates were significantly better (p < 0.01) for patients with pT2 than for those with pT3 tumors (79% vs. 50% and 59% vs. 35%, respectively). Involvement of regional lymph nodes (N+) was an important prognostic factor for survival in patients with pT3 tumors. The 5-year survival for pT3 N+ was 39%, compared with 66% in those with pT3N0 (p < 0.01). Preoperative embolization was also an important factor influencing survival. The overall 5- and 10-year survival for 118 patients embolized before nephrectomy was 62% and 47%, respectively, and it was 35% and 23%, respectively, for the matched group of 116 patients treated with surgery alone (p = 0.01). The most important finding of this study was an apparent importance of preoperative embolization in improving patients’ survival. This finding needs to be interpreted with caution and confirmed in a prospective randomized trial.
ISSN:0277-3732
出版商:OVID
年代:2000
数据来源: OVID
|
3. |
A Phase II Trial of Tamoxifen, Ifosfamide, Epirubicin, and Cisplatin Combination Chemotherapy for Inoperable Non–Small-Cell Lung Cancer |
|
American Journal of Clinical Oncology: Cancer Clinical Trials,
Volume 23,
Issue 1,
2000,
Page 13-17
Yuh Chen,
Reury Perng,
Kuang Yang,
Wei Lin,
Hsiao Wu,
Jacqueline Liu,
Chun Tsai,
Jacqueline Whang-Peng,
Preview
|
|
摘要:
A phase II trial of tamoxifen, ifosfamide, epirubicin, and cisplatin (TIEP) chemotherapy was conducted in patients with chemonaive inoperable non–small-cell lung cancer (NSCLC) to assess response and toxicity. From October 1997 to August 1998, 19 patients were treated. The treatment schema included tamoxifen 60 mg twice daily by mouth on days 1 to 3, ifosfamide 3 g/m2intravenous infusion (IV) 60 minutes with mesna on day 2, epirubicin 50 mg/m2IV bolus on day 2, and cisplatin 60 mg/m2IV 60 minutes on day 2 every 4 weeks for up to six cycles. All patients were evaluable for response and toxicity. The major toxicity was myelosuppression; grade 3 or 4 leukopenia or neutropenia occurred in 14 of 19 (73.7%) patients during treatment, and 6 patients (31.6%) experienced fever in association with the neutropenia; no toxic deaths occurred. Grade 3 anemia occurred in six patients (31.6%) during the treatment. Grade 3 or 4 nausea/vomiting occurred in only one patient. Toxicities other than neutropenia and anemia were minimal. After two cycles of treatment, 9 of 19 patients attained a partial response (47.4%, 95% confidence interval 24.9%–69.9%) in this study. The median time to disease progression was 6 months and median survival time was 12 months. We conclude that TIEP is an active combination regimen with an acceptable toxicity profile in Chinese patients with inoperable NSCLC.
ISSN:0277-3732
出版商:OVID
年代:2000
数据来源: OVID
|
4. |
Late Pulmonary Effects in Favorable Stage I and IIA Hodgkin’s Disease Treated With Radiotherapy Alone |
|
American Journal of Clinical Oncology: Cancer Clinical Trials,
Volume 23,
Issue 1,
2000,
Page 18-21
Fabrizio Villani,
Simonetta Viviani,
Valeria Bonfante,
Patrizia De Maria,
Fulvia Soncini,
A. Laffranchi,
Preview
|
|
摘要:
Radiotherapy (RT) in patients with favorable-stage Hodgkin’s disease can induce clinical and subclinical evidence of pulmonary damage lasting over the years. In this study, we monitored 36 patients with stage IA–IIA Hodgkin’s disease treated with subtotal nodal RT. The planned dose of RT was 40 Gy to 44 Gy to the involved areas and 36 Gy to the adjacent uninvolved areas. Pulmonary function was evaluated by chest radiograph, spirometric parameters, arterial blood gas analysis, and single-breath CO transfer factor (DLCO). The tests were performed before and at the end of irradiation, and during the follow-up 1 and 3 to 5 years after the treatment. At the end of RT, we found a significant decrease of total lung capacity, vital capacity, forced expiratory volume in 1 second, residual volume, and DLCO. Spirometric parameters improved during the follow-up period, whereas the decline of DLCO (−6.4%) was persistent. No correlation was found between mantle RT dose and DLCO changes. Four patients showed a decline of DLCO of >20% from pretreatment values but only one was symptomatic. Our study confirms that RT induces a pulmonary-restrictive disease at a subclinical level that seems to be reversible in the majority of patients.
ISSN:0277-3732
出版商:OVID
年代:2000
数据来源: OVID
|
5. |
Ambamustine in the Second-Line Treatment of Patients With Small-Cell Lung CancerA Phase II Fonicap Study |
|
American Journal of Clinical Oncology: Cancer Clinical Trials,
Volume 23,
Issue 1,
2000,
Page 22-25
A. Ardizzoni,
G. Antonelli,
S. Ricci,
G. Frasci,
M. Rinaldi,
L. Boni,
P. Galletti,
M. Pennucci,
A. Antonuzzo,
A. Gravina,
L. Galli,
G. Comella,
P. Conte,
F. Salvati,
R. Rosso,
Preview
|
|
摘要:
Despite a high probability of response to first-line chemotherapy, most patients with small-cell lung cancer (SCLC) will eventually have progression of their disease because of the development of resistant disease. Second-line testing of new drugs is an accepted research strategy in SCLC. In this context, the Italian Lung Cancer Task Force (FONICAP) has tested a new synthetic bifunctional alkylating agent, Ambamustine, with preliminary evidence of activity in other solid tumors. Patients with measurable SCLC, progressive after one first-line chemotherapy regimen (either “sensitive” or “refractory”), were eligible for the study. Ambamustine was administered at the dose of 2 mg/kg as a 1-hour intravenous infusion on day 1 every 21 days. The dose was to be increased to 3 mg/kg if no grade IV toxicity and complete hematologic recovery had occurred by day 22. Sample size was calculated according to a two-stage optimal Simon’s design. Seventeen patients were entered into the study. Twelve patients were refractory to prior chemotherapy; 12 had extensive disease; the median age was 64 years (range: 46–75 years) and the median performance status was 1. Among 13 patients who received more than one cycle, 9 patients could increase Ambamustine dose from 2 to 3 mg/kg. No objective response was observed: one patient obtained a 50% regression of the primary tumor with contemporary disease progression in the liver and was qualified as having progressive disease. The treatment was well tolerated: grade IV leukopenia occurred in only 1 patient; grade III anemia occurred in 17.6%, grade III leukopenia in 11.8%, and grade III thrombocytopenia in 23.5%. Nonhematologic toxicity was minimal. Ambamustine, at the dose and schedule used in this study, is well tolerated in pretreated patients with SCLC but has no significant antitumor activity in this unfavorable group of patients.
ISSN:0277-3732
出版商:OVID
年代:2000
数据来源: OVID
|
6. |
Kaposi Sarcoma After Treatment of Hodgkin’s Disease in a Young Adult Non-AIDS PatientCase Report and Review |
|
American Journal of Clinical Oncology: Cancer Clinical Trials,
Volume 23,
Issue 1,
2000,
Page 26-28
Melvin Deutsch,
Samuel Jacobs,
Preview
|
|
摘要:
We describe a young woman diagnosed with Hodgkin’s disease, stage I, at age 20 years. She delayed treatment until age 23, at which time she was considered to have stage II-A disease and was then treated with chemotherapy and involved field irradiation. Two years later, Kaposi sarcoma, which developed on her right shoulder, was excised. Both the Hodgkin’s disease and Kaposi sarcoma appeared to be cured, but 3 years later, acute myelogenous leukemia developed and the patient subsequently died in relapse. This is one of the very few instances of a young patient, not infected with the AIDS virus, in whom Kaposi sarcoma developed as a second malignancy after treatment of Hodgkin’s disease.
ISSN:0277-3732
出版商:OVID
年代:2000
数据来源: OVID
|
7. |
‘Full Dose’ Reirradiation of Human Cervical Spinal Cord |
|
American Journal of Clinical Oncology: Cancer Clinical Trials,
Volume 23,
Issue 1,
2000,
Page 29-31
Samuel Ryu,
Sri Gorty,
Ann Kazee,
Jeffrey Bogart,
Seung Hahn,
Pankaj Dalal,
Chung Chung,
Robert Sagerman,
Preview
|
|
摘要:
With the progress of modern multimodality cancer treatment, retreatment of late recurrences or second tumors became more commonly encountered in management of patients with cancer. Spinal cord retreatment with radiation is a common problem in this regard. Because radiation myelopathy may result in functional deficits, many oncologists are concerned about radiation-induced myelopathy when retreating tumors located within or immediately adjacent to the previous radiation portal. The treatment decision is complicated because it requires a pertinent assessment of prognostic factors with and without reirradiation, radiobiologic estimation of recovery of occult spinal cord damage from the previous treatment, as well as interactions because of multimodality treatment. Recent studies regarding reirradiation of spinal cord in animals using limb paralysis as an endpoint have shown substantial and almost complete recovery of spinal cord injury after a sufficient time after the initial radiotherapy. We report a case of “full” dose reirradiation of the entire cervical spinal cord in a patient who has not developed clinically detectable radiation-induced myelopathy on long-term follow-up of 17 years after the first radiotherapy and 5 years after the second radiotherapy.
ISSN:0277-3732
出版商:OVID
年代:2000
数据来源: OVID
|
8. |
Thoracic Wall Prosthesis Prevents Deep Invasion by Non–Small-Cell Lung Cancer |
|
American Journal of Clinical Oncology: Cancer Clinical Trials,
Volume 23,
Issue 1,
2000,
Page 32-33
Y. Mentens,
D. Schrijvers,
J. Van den Brande,
P. Van Schil,
J. Vermorken,
Preview
|
|
摘要:
Chest wall invasion is found in 5% of patients with non–small-cell lung cancer. Treatment for localized non–small-cell lung cancer consists of surgical resection and/or radiotherapy. We report a patient with lung cancer who had a local relapse after a reconstruction of the thoracic wall with a soft-tissue patch. Chemotherapy was given before reresection of the local relapse. Postoperative radiation therapy was performed. Twenty-one months after treatment for recurrent disease, the patient remains in complete remission. The history of this patient shows that a soft-tissue patch may prevent local tumor invasion. A review of the literature is given.
ISSN:0277-3732
出版商:OVID
年代:2000
数据来源: OVID
|
9. |
Sustained Ventricular Tachycardia and Its Successful Prophylaxis During High-Dose Bolus Interleukin-2 Therapy for Metastatic Renal Cell Carcinoma |
|
American Journal of Clinical Oncology: Cancer Clinical Trials,
Volume 23,
Issue 1,
2000,
Page 34-36
Leslie Oleksowicz,
Paul Escott,
Gail Leichman,
Edward Spangenthal,
Preview
|
|
摘要:
In the setting of interleukin-2 (IL-2) administration, tachycardias of ventricular origin are classified as serious, grade IV toxicities, necessitating the discontinuation of therapy. In this report, we describe a patient with renal cell carcinoma who experienced ventricular tachycardia while undergoing treatment with high-dose bolus IL-2. Prophylaxis with sotalol permitted the successful completion of his first cycle of treatment, without any recurrent rhythm disturbances.
ISSN:0277-3732
出版商:OVID
年代:2000
数据来源: OVID
|
10. |
A Phase II Trial of 5-Fluorouracil, Leucovorin, and Interferon Alpha 2A (IFN-&agr; 2a) in Metastatic Pancreatic CarcinomaA Penn Cancer Clinical Trials Group (PCCTG) Trial |
|
American Journal of Clinical Oncology: Cancer Clinical Trials,
Volume 23,
Issue 1,
2000,
Page 37-39
Alice David,
David Vaughn,
Christopher Holroyde,
Barbara Armstead,
Daniel Haller,
Preview
|
|
摘要:
A phase II study was performed to evaluate the activity and toxicity of 5-fluorouracil (5-FU), leucovorin, and inteferon &agr;-2a in metastatic pancreatic carcinoma. Twenty-three patients were entered in this study. Four patients withdrew before receiving treatment and one patient was nonevaluable for response because of treatment-related toxicity. The most common significant toxicity was nausea and vomiting. Treatment-related hospitalization was significant. Of 18 evaluable patients, 4 maintained stable disease and 14 had disease progression. None had an objective clinical response. We conclude that this biochemically modulated 5-FU regimen is ineffective treatment for advanced pancreatic carcinoma, with significant toxicity even in highly selected patients with an ambulatory performance status.
ISSN:0277-3732
出版商:OVID
年代:2000
数据来源: OVID
|
|